GI
ACRS icon

GAMMA Investing’s Aclaris Therapeutics ACRS Stock Holding History

GAMMA Investing’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.4K Hold
1,020
– – ﹤0.01% 3435
2026
Q1 		$3.83K Buy
1,020
+791
+345% +$2.67K ﹤0.01% 3467
2025
Q4 		$689 Buy
+229
New +$579 ﹤0.01% 3865

Other funds holding ACRS

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
CAL
Capital Advisors Ltd Shaker Heights, Ohio $991M AUM 19.82% 1-Year Est. Return

GAMMA Investing's ACRS Position: Q2 2026 in Review

GAMMA Investing held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 1,020 shares worth $5.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3435.

GAMMA Investing first reported a position in ACRS in Q4 2025 and has held it in 3 quarters since. 7 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • GAMMA Investing held 1,020 shares of Aclaris Therapeutics worth $5.4K as of Q2 2026.
  • GAMMA Investing left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3435 holding.
  • GAMMA Investing first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 7 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.